Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JANX007 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | IV dosing during 21- or 28-day cycles. Dosage per cohort will increase to determine the maximum tolerable dose. |
| Backfill Expansion | EXPERIMENTAL | IV dosing during 21- or 28-day cycles. Subjects will be dosed at levels previously declared tolerable. |
| Monotherapy Expansion Parts A - D | EXPERIMENTAL | IV dosing during 21- or 28-day cycles. Subjects will be dosed at preliminary recommended phase 2 dose (RP2D). |
| Combination Expansion | EXPERIMENTAL | IV dosing during 21- or 28-day cycles. Subjects will be dosed at preliminary recommended phase 2 dose |
| Name | Type | Description |
|---|---|---|
| JANX007 | BIOLOGICAL | JANX007 is dosed via IV in a 21- or 28-day cycle. |
| Darolutamide | DRUG | Darolutamide is dosed via oral tablets |
Inclusion Criteria: * Male ≥18 years of age at the time of signing informed consent * Histologically or cytologically confirmed adenocarcinoma of the prostate * For Dose Escalation and Backfill: Having mCRPC that progressed after at least one novel anti-androgen therapy and at least one taxane cont...
Top 20 of 49 competitors
JANX007 is an investigational monoclonal antibody being developed for prostate cancer, specifically metastatic castration-resistant prostate cancer. It is currently in Phase 1 clinical development and is not yet approved by the FDA.
JANX007 targets PSMA, or prostate-specific membrane antigen, a protein commonly expressed on prostate cancer cells. By binding to PSMA, the antibody is designed to direct an immune response against PSMA-expressing tumor cells.
JANX007 is being developed by Janux Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol JANX. The company is conducting clinical trials to evaluate the drug's safety and efficacy.
JANX007 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to assess its safety and effectiveness.
JANX007 is being studied in a Phase 1 clinical trial with the identifier NCT05519449, titled 'Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)'. The trial is recruiting participants in the United States and Australia, with an enrollment target of 272 male patients aged 18 years and older.
JANX007 is the investigational name for this specific monoclonal antibody developed by Janux Therapeutics. No alternative names have been reported for this drug in the available clinical trial information.